- Details
- Sam Chang speaks with Tara Cumming and Meredith Donahue who share their insights on implementing an efficient system for administering instillation therapy for bladder cancer patients at Vanderbilt. Cumming and Donahue were instrumental in designing this streamlined process, which they call the BCG Clinic, where patients receive treatment one day each week, improving not just patient care but also...
|
- Details
- Ruchika Talwar hosts a conversation with Brian Chun to discuss Chun's study on the impacts of the BCG drug shortage, a problem that has plagued urologists nationwide for nearly a decade, on the treatment of non-muscle invasive bladder cancer. Chun's research, conducted through a review of Medicare claims data from 2010 to 2017, reveals a decrease in BCG use across the country and a considerable st...
|
- Details
- Domenique Escobar discusses her study on Fibroblast Activated Protein (FAP) PET imaging for localized bladder cancer in this conversation with Wei Shen Tan. She explains that FAP PET, a new diagnostic tool that targets proteins on cancer-associated fibroblasts, shows potential for more accurate disease staging and treatment pathways for patients. Compared to conventional imaging methods like CT, M...
|
- Details
- Ashish Kamat welcomes John Taylor, III to discuss the importance of preclinical models in advancing medical innovation. He details two models based on the N-Butyl N(4-hydroxybutyl) nitrosamine (BBN) model, which is a reliable model for bladder-exclusive tumors. Taylor speaks about the benefits of the BBN model in studying muscle invasive bladder cancer, yet also underlines its shortcomings in stud...
|
- Details
- Ashish Kamat hosts Roberto Contieri, who shares his work on active surveillance as a treatment approach for low-risk non-muscle-invasive bladder cancer. Highlighting that 75% of bladder cancer patients present with non-muscle-invasive disease, he explores the merits of a conservative approach, noting its cost-effectiveness, safety, and minimal surgical risk. Contieri presents findings from the BIA...
|
- Details
- Stephen Williams and Sam Chang discuss the relationship between Agent Orange and bladder cancer. They highlight a retrospective cohort study conducted on over 25 million veterans to determine the association between Agent Orange exposure and bladder cancer incidence. The study controlled for various factors and found a slight increase in bladder cancer risk among veterans exposed to Agent Orange....
|
- Details
- Sam Chang is joined by Chad Ritch for a discussion on tumor biomarkers and urothelial carcinoma. They discuss various types of biomarkers, including tissue-based and liquid-based markers. In the context of non-invasive bladder cancer, they mention the use of cytology as the standard despite its limitations in sensitivity. They also highlight the potential of RNA-based urinary biomarkers, such as C...
|
- Details
- Katie Murray joins Ashish Kamat discusses optimizing care for bladder cancer in women. Dr. Murray highlights the need to understand the biologic and diagnostic differences, as well as the timing of diagnoses and survival disparities in bladder cancer among women. She emphasizes the importance of raising awareness among primary care physicians and advocating for early diagnosis, as women often expe...
|
- Details
- Sam Chang is joined by Patrick Soon-Shiong for a discussion on the effectiveness of N-803 for BCG unresponsive bladder cancer. They discussed the importance of an ideal profile for such an agent, which includes complete remission rate, durability of the response, and high cystectomy avoidance rate. They also highlighted the importance of the agent's safety and tolerability for urologists. The N-80...
|
- Details
- Roger Li joins Ashish Kamat to discuss the CG0070 adenovirus vector and its potential use in combination with immune checkpoint blockade for patients with BCG unresponsive bladder cancer. The combination therapy has shown promising preliminary results, with 20 out of 22 patients achieving a complete response at three months and six out of eight patients maintaining a complete response at 12 months...
|
